Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population, 2004–2019.

Autor: Winchar, Kelcey, Lambert, Pascal, McManus, Kirk J., Chodirker, Bernie, Kean, Sarah, Serfas, Kim, Decker, Kathleen, Nachtigal, Mark W., Altman, Alon D.
Předmět:
Zdroj: Current Oncology; Dec2022, Vol. 29 Issue 12, p9365-9376, 12p, 5 Charts, 2 Graphs
Abstrakt: Simple Summary: This study was performed to better understand rates and factors that influence patients in accepting a referral to genetics or testing for genes that predispose them to ovarian cancer (BRCA1/2). Using multiple provincial databases and registries, the study team looked at data from 944 patients with high-grade ovarian cancer between 2004–2019. We found that the rate of genetic referrals fluctuated over time; however, the rate of genetic testing increased over the entire timeframe. Factors found to increase rates of referral and testing included age, cancer histology, history of oral contraceptive use, and family history of ovarian cancer. Increasing the rate of genetic testing will help patients and their health care team plan clinical management and treatment. (1) Background: The primary objective of this study was to examine the rate of genetic referral, BRCA testing, and BRCA positivity amongst all patients with high-grade serous ovarian cancers (HGSOC) from 2004–2019. The secondary objective was to analyze secondary factors that may affect the rates of referral and testing. (2) Methods: This population-based cohort study included all women diagnosed with HGSOC using the Manitoba Cancer Registry, CervixCheck registry, Medical Claims database at Manitoba Health, the Hospital Discharge abstract, the Population Registry, and Winnipeg Regional Health Authority genetics data. Data were examined for three different time cohorts (2004–2013, 2014–2016; 2017–2019) correlating to practice pattern changes. (3) Results: A total of 944 patients were diagnosed with HGSOC. The rate of genetic referrals changed over the three timeframes (20.0% → 56.7% → 36.6%) and rate of genetic testing increased over the entire timeframe. Factors found to increase rates of referral and testing included age, histology, history of oral contraceptive use, and family history of ovarian cancer. Prior health care utilization indicators did not affect genetic referral or testing. (4) Conclusion: The rate of genetic referral (2004–2016) and BRCA1/2 testing (2004–2019) for patients with a diagnosis of HGSOC increased over time. A minority of patients received a consultation for genetics counselling, and even fewer received testing for a BRCA1/2. Without a genetic result, it is difficult for clinicians to inform treatment decisions. Additional efforts are needed to increase genetics consultation and testing for Manitoban patients with HGSOC. Effects of routine tumour testing on rates of genetic referral will have to be examined in future studies. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje